Similarly, a small cohort of 38 patients with inoperable HNSCC treated with chemoradiotherapy [93] showed that TP53 mutations—either persistent or newly emerging post-treatment—were associated with advanced T stage and poorer outcomes. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.